Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Andi, Chin"'
Autor:
Jeff Schein, Ann Childress, Martin Cloutier, Urvi Desai, Andi Chin, Mark Simes, Annie Guerin, Julie Adams
Publikováno v:
BMC Psychiatry, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Adults with attention-deficit hyperactivity disorder (ADHD) often cycle through multiple treatments for reasons that are not well documented. This study analyzed the reasons underlying treatment changes among adults treated for AD
Externí odkaz:
https://doaj.org/article/3ca38d23149c44a9a7137a899626888f
Autor:
Neal, Shore, Shan, Jiang, Viviana, Garcia-Horton, Emi, Terasawa, David, Steffen, Andi, Chin, Rajeev, Ayyagari, Jamie, Partridge, A Reginald, Waldeck
Publikováno v:
Advances in Therapy. 39:5025-5042
Three novel androgen receptor inhibitors are approved in the USA for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC): apalutamide, enzalutamide, and darolutamide. All three therapies have demonstrated prolonged metastasi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52d39ee61cc00e5bad4b07988c648c6a
https://doi.org/10.1007/s12325-022-02245-8
https://doi.org/10.1007/s12325-022-02245-8
Autor:
Andreas Reiter, Jason Gotlib, Iván Álvarez-Twose, Deepti H. Radia, Johannes Lübke, Priyanka J. Bobbili, Aolin Wang, Chelsea Norregaard, Saša Dimitrijevic, Erin Sullivan, Melinda Louie-Gao, Juliana Schwaab, Ilene A. Galinsky, Cecelia Perkins, Wolfgang R. Sperr, Priya Sriskandarajah, Andi Chin, Selvam R. Sendhil, Mei Sheng Duh, Peter Valent, Daniel J. DeAngelo
Publikováno v:
Leukemia. 36:2108-2120
Advanced systemic mastocytosis (AdvSM) is a rare myeloid neoplasm associated with poor overall survival (OS). This study (NCT04695431) compared clinical outcomes between patients with AdvSM treated with avapritinib in the Phase 1 EXPLORER (NCT0256198
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::328e84008f695ad671d5dc3e26b468ea
https://doi.org/10.1038/s41375-022-01615-z
https://doi.org/10.1038/s41375-022-01615-z
Autor:
Bradley McGregor, Daniel M. Geynisman, Mauricio Burotto, Cristina Suárez, Maria T. Bourlon, Pedro C. Barata, Shuchi Gulati, Stephen Huo, Flavia Ejzykowicz, Steven I. Blum, Viviana Del Tejo, Melissa Hamilton, Jessica R. May, Ella X. Du, Aozhou Wu, Pavol Kral, Cristina Ivanescu, Andi Chin, Keith A. Betts, Chung-Han Lee, Toni K. Choueiri, David Cella, Camillo Porta
Publikováno v:
European Urology Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cbf4b42a283a34e4313b7163bcedee06
https://doi.org/10.1016/j.euo.2023.01.012
https://doi.org/10.1016/j.euo.2023.01.012
Autor:
Andreas Reiter, Jason Gotlib, Iván Álvarez-Twose, Deepti Radia, Johannes Lübke, Priyanka Bobbili ScD, Aolin Wang, Chelsea Norregaard, Saša Dimitrijević, Erin Sullivan, Melinda Louie-Gao, Juliana Schwaab, Ilene Galinsky, Cecelia Perkins, Wolfgang Sperr, Priya Sriskandarajah, Andi Chin, Selvam Sendhil, Mei Sheng Duh ScD, Peter Valent, Daniel DeAngelo
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S159
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c28ab28018850013a0a5ef8edba8b002
https://doi.org/10.1016/s2152-2650(22)00975-2
https://doi.org/10.1016/s2152-2650(22)00975-2
Autor:
Andreas Reiter, Jason Gotlib, Iván Álvarez-Twose, Deepti Radia, Johannes Lübke, Priyanka Bobbili ScD, Aolin Wang, Chelsea Norregaard, Saša Dimitrijević, Erin Sullivan, Melinda Louie-Gao, Juliana Schwaab, Ilene Galinsky, Cecelia Perkins, Wolfgang Sperr, Priya Sriskandarajah, Andi Chin, Selvam Sendhil, Mei Sheng Duh ScD, Peter Valent, Daniel DeAngelo
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S337
Avapritinib, a selective KIT D816V inhibitor, was approved by the FDA and EMA (by EMA only after prior systemic therapy) for treating adults with advanced systemic mastocytosis (AdvSM) based on the single-arm phase 1 EXPLORER (NCT02561988) and phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a2adc71552ad825deec5e57251939a5
https://doi.org/10.1016/s2152-2650(22)01459-8
https://doi.org/10.1016/s2152-2650(22)01459-8
Autor:
Bradley Alexander McGregor, Mauricio Burotto, Shuchi Gulati, Daniel M. Geynisman, Camillo Porta, Pedro C. Barata, Brian Stwalley, Ella X Du, Maria T Bourlon, Keith A. Betts, Aozhou Wu, Andi Chin, S. Huo, Toni K. Choueiri, Cristina Suarez Rodriguez, Viviana Del Tejo
Publikováno v:
Journal of Clinical Oncology. 39:4578-4578
4578 Background: Nivolumab in combination with cabozantinib (N+C) has demonstrated significantly improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS), compared with sunitinib as a first-line (1L) treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de2b95ea75c6eb8729054e89409b60a6
https://doi.org/10.1200/jco.2021.39.15_suppl.4578
https://doi.org/10.1200/jco.2021.39.15_suppl.4578